Prehabilitation and Rehabilitation in PAD (PREPARE-IT)

August 19, 2024 updated by: Jonathan Myers, Palo Alto Veterans Institute for Research

Prehabilitation and Rehabilitation in PAD: A Randomized Exercise Intervention Trial (PREPARE-IT)

To determine the effectiveness of pre and post-operative exercise therapy in patients undergoing peripheral artery stenting for peripheral arterial disease.

Study Overview

Detailed Description

Peripheral artery disease (PAD) is a form of cardiovascular disease that affects the arteries supplying blood flow to the legs. The prevalence of PAD is increasing rapidly in the United States. When PAD is severe, it can cause pain with movement and limit a person's ability to walk or perform their normal daily activities. With severe PAD, a procedure is often performed in which an artery is held open with a small tube called a stent.

Programs of exercise-based rehabilitation have been shown to greatly help these patients in terms of the pain they experience with walking, their ability to perform daily activities or those required by work, and improved quality of life. There is also a newer form of therapy, called prehabilitation, which has been shown to have important benefits for patients with PAD. Prehabilitation involves four to six weeks of exercise therapy and lifestyle recommendations before undergoing a stent procedure. Prehabilitation helps patients improve exercise tolerance and make lifestyle changes that improve risk factors before the procedure. Those who participate in prehabilitation programs have fewer complications with the stent procedure, spend fewer days in the hospital, and have a better ability to exercise and return to work more quickly.

Although the benefits of prehabilitation and rehabilitation are well established, most doctors neglect to recommend these treatments to their patients who undergo a stent procedure for PAD. The research team will study the impact of prehabilitation, rehabilitation or both forms of therapy. The results will likely encourage more doctors to recommend the best option for their patients, and possibly to recommend both prehabilitation and rehabilitation among patients who are having a stent procedure.

Study Type

Interventional

Enrollment (Estimated)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Jonathan N Myers, PhD
  • Phone Number: 64661 650-493-5000
  • Email: drj993@aol.com

Study Contact Backup

Study Locations

    • California
      • Palo Alto, California, United States, 94304
        • Recruiting
        • VA Palo Alto Health Care System
        • Contact:
          • Jonathan N Myers, PhD
          • Phone Number: 64661 650-493-5000
          • Email: drj993@aol.com
        • Contact:
        • Principal Investigator:
          • Jonathan N Myers, PhD
        • Sub-Investigator:
          • Charles G Gronau, DCEP
        • Sub-Investigator:
          • Khin N Chan, MD
        • Sub-Investigator:
          • Pallavi Gautam, MPT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or Female adult diagnosed with peripheral artery disease (PAD)
  • Experiencing leg pain while walking
  • Scheduled to have a stent for PAD
  • Able to perform exercise safely
  • Postmenopausal and not of child bearing capacity

Exclusion Criteria:

  • Medically unstable patients
  • Recent MI within 3 months
  • Malignancy
  • Uncontrolled diabetes mellitus (HBA1C ≥8 mmol/l)
  • Alcoholism or other recreational drug use

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prehabilitation
Subjects randomized to the prehabilitation group will undergo 6 weeks of individualized exercise therapy, including a 1-week ramp-up period (3 sessions) conducted at the VAPAHCS rehabilitation facility. Subjects will then exercise primarily at home, with an in-clinic exercise session repeated weekly for the duration of their participation. These sessions will be individualized based on tolerance and in accordance with standardized guidelines, but will generally consist of 45-60 min of supervised exercise that combines aerobic and resistance training, including warm-up and cool-down. Throughout the study, subjects will be asked to perform 30 minutes of daily unsupervised aerobic exercise of their choice, with an emphasis on improving walking performance at home. Guidelines for patient monitoring, safety, and prescription outlined by the American Heart Association, American College Sports Medicine, and American Association of Cardiovascular and Pulmonary Rehabilitation will be followed.
Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.
Other Names:
  • Exercise Therapy
The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.
Active Comparator: Rehabilitation
Subjects randomized to the rehabilitation group will initiate exercise sessions approximately 2-weeks following endovascular intervention as outlined in guidelines for PAD. Patient stability and wound patency will be paramount considerations prior to a patient beginning the rehabilitation program. Similar to prehabilitation, subjects will undergo a 1-week, 3 session familiarization period conducted at the VAPAHCS rehabilitation facility, then return once weekly for in-clinic supervised sessions. The weekly in-person visits will be conducted at the rehabilitation center to monitor and encourage compliance, review activity questionnaires, download accelerometry data, and address any clinical concerns. Similar to participants in the prehabilitation group, the 6-week rehabilitation period will be individualized and follow standardized guidelines designed for rehabilitation in patients with PAD.
Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.
Other Names:
  • Exercise Therapy
The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.
Experimental: Prehabiliation and Rehabilitation
Subjects randomized to the prehabilitation and rehabilitation group will undergo both the 6 weeks of prehabilitation pre-operative and 6 weeks of rehabilitation post-operative as described in their respective arm descriptions.
Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.
Other Names:
  • Exercise Therapy
The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to claudication pain
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Time to initial onset of claudication pain with exercise treadmill test.
Baseline, 6 weeks, 14 weeks, 22 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peak VO2
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Peak V02 will be determined on a treadmill using an individualized ramp protocol with collection of continuous ventilatory gas exchange responses.
Baseline, 6 weeks, 14 weeks, 22 weeks
6-minute walk test (6MWT)
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Total distance (meters) of walk in 6 minutes.
Baseline, 6 weeks, 14 weeks, 22 weeks
Walking Impairment Questionnaire (WIQ)
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Developed to evaluate walking limitations in patients with PAD. Assesses the ability of individuals to walk defined distances and speeds and climb stairs.
Baseline, 6 weeks, 14 weeks, 22 weeks
Peripheral Artery Questionnaire (PAQ)
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
20-item questionnaire developed and validated specifically for PAD and is designed to quantify patients' physical limitations, symptoms, social function, treatment satisfaction, and quality of life.
Baseline, 6 weeks, 14 weeks, 22 weeks
Walking
Time Frame: Up to 22 weeks
Physical activity patterns, expressed as steps/day will be quantified using fitness/health tracking device.
Up to 22 weeks
Energy expenditure
Time Frame: Up to 22 weeks
Energy expenditure will be quantified using fitness/health tracking device.
Up to 22 weeks
Chair raises
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Number of repetitions completed within 60 seconds (46cm high seat).
Baseline, 6 weeks, 14 weeks, 22 weeks
Upper body strength
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
1 repetition max for Chest Press.
Baseline, 6 weeks, 14 weeks, 22 weeks
Lower body strength
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
1 repetition max for Leg Extension.
Baseline, 6 weeks, 14 weeks, 22 weeks
Hand grip strength
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Maximum isometric strength will be measured using a hand grip dynamometer.
Baseline, 6 weeks, 14 weeks, 22 weeks
Insulin sensitivity
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Fasting glucose and insulin samples will be obtained from blood draw to generate Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score.
Baseline, 6 weeks, 14 weeks, 22 weeks
Lipid panel
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Fasting total cholesterol, LDL, HDL and triglycerides will be assessed from blood draw.
Baseline, 6 weeks, 14 weeks, 22 weeks
Sodium
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Standard Chem 20 blood draw will be used to obtain sodium in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
Homocysteine
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Homocysteine will be assessed from blood draw.
Baseline, 6 weeks, 14 weeks, 22 weeks
High-sensitivity C-reactive protein (hs-CRP)
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
High-sensitivity C-reactive protein (hs-CRP) will be assessed from blood draw.
Baseline, 6 weeks, 14 weeks, 22 weeks
Interleukin-6 (IL-6)
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Interleukin-6 (IL-6) will be assessed from blood draw.
Baseline, 6 weeks, 14 weeks, 22 weeks
D-dimer
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
D-dimer will be assessed from blood draw.
Baseline, 6 weeks, 14 weeks, 22 weeks
Blood protein
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain blood protein value.
Baseline, 6 weeks, 14 weeks, 22 weeks
Albumin
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain albumin in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
Calcium
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain calcium in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
Potassium
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain potassium in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
Chloride
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain chloride in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
Carbon dioxide
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain carbon dioxide in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
AST/GOTU/l
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain AST/GOTU/l in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
ALT/GPT
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain ALT/GPT in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
ALK Phosphatase
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain ALT/GPT in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
Bilirubin
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain total bilirubin in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
Urea Nitrogen
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain urea nitrogen in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
Creatinine
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain creatinine in blood value.
Baseline, 6 weeks, 14 weeks, 22 weeks
eGFR
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Blood draw will be used to obtain eGFR value.
Baseline, 6 weeks, 14 weeks, 22 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Endothelial function
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
The Endo Pat 2000 system will be used to perform this procedure. Both forearms will be occluded with a standard blood pressure cuff for 5 minutes.
Baseline, 6 weeks, 14 weeks, 22 weeks
Ankle-brachial index (ABI)
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Using a standard brachial artery cuff method with a Doppler ultrasound probe at the posterior tibial artery to determine ABI.
Baseline, 6 weeks, 14 weeks, 22 weeks
Exercise Benefits and Barriers Scale (EBBS)
Time Frame: Baseline, 6 weeks, 14 weeks, 22 weeks
Perceived barriers and benefits to physical activity will be assessed using two methods: a semi-structured interview and administration of the Exercise Benefits and Barriers Scale (EBBS), to obtain both open-ended qualitative and quantitative data on these constructs. The EBBS may be used in its entirety or as two seperate scales. As a whole, scoring for EBBS ranges from 43 to 172 with a higher score being the individual perceives exercise more positively. When the Benefits Scale is used alone, the score range is between 29 to 116 with the higher the score being the individual perceives exercise more positively. When the Barriers Scale is used alone, the score range is between 14 to 56. The higher the score on the Barriers Scale, the greater the perception of barriers to exercise.
Baseline, 6 weeks, 14 weeks, 22 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 7, 2024

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

July 25, 2027

Study Registration Dates

First Submitted

August 13, 2024

First Submitted That Met QC Criteria

August 19, 2024

First Posted (Actual)

August 22, 2024

Study Record Updates

Last Update Posted (Actual)

August 22, 2024

Last Update Submitted That Met QC Criteria

August 19, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripheral Arterial Disease

Clinical Trials on Exercise Intervention

Subscribe